SCHEMBL21875183

SCHEMBL21875183

COC(=O)c1cn(S(=O)(=O)c2ccc(C)cc2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.49
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
FFAR4 Q5NUL3 1/20 0.46
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.43
KDM4E B2RXH2 3/20 0.43
CYP2C9 P11712 3/20 0.43
TSHR P16473 2/20 0.43
LMNA P02545 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
MMP2 P08253 1/20 0.41
ANPEP P15144 1/20 0.41
MAPK1 P28482 2/20 0.40
GLA P06280 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21807392 0.92 FBP1 (0.53) FBP1CA1CA2FFAR4CA12
SCHEMBL21875150 0.83 CA1 (0.50) CA1CA2KDM4ETSHRLMNA
SCHEMBL31728066 0.78 LMNA (0.64) CA1CA2CA12CA9KMT2A
SCHEMBL4501807 0.77 FBP1 (0.60) FBP1CA1CA2CYP2C9TSHR
SCHEMBL9700742 0.75 MEN1 (0.51) FBP1CA1CA2FFAR4CA12
SCHEMBL12675200 0.74 TSHR (0.51) CA12CA9KMT2AMEN1KDM4E
SCHEMBL2563438 0.74 FBP1 (0.44) FBP1CA1CA2FFAR4CA12
SCHEMBL18584669 0.72 MEN1 (0.54) CA2FFAR4CA9KMT2AMEN1
SCHEMBL12674582 0.72 KLKB1 (0.51) CA1CA2KMT2AMEN1KDM4E
SCHEMBL19859664 0.71 GRM4 (0.51) FBP1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3873891-A1 ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS KV3 POTASSIUM CHANNEL ACTIVATORS H. Lundbeck A/S (DK) 2021-09-08 EP disclosed
CN-113056461-A Arylsulfonyl pyrrole carboxamide derivatives as Kv3 potassium channel activators H.隆德贝克有限公司 2021-06-29 CN disclosed
US-20200131156-A1 ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS H. LUNDBECK A/S (DK) 2020-04-30 US disclosed
US-20200131156-A1 ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS H. LUNDBECK A/S (DK) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200131156-A1 ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS KCNA3, KCNN3, KCNK3 FBP1 3444/4885CA1 3447/4885CA2 1008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.